Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2770Triple Negative Breast Neoplasms 407Neoplasm Metastasis 156Breast Neoplasms, Male 102Neoplasms 100Ovarian Neoplasms 69Carcinoma, Non-Small-Cell Lung 68Carcinoma, Intraductal, Noninfiltrating 68Lung Neoplasms 66Brain Neoplasms 60Colorectal Neoplasms 52Inflammatory Breast Neoplasms 50Advanced Breast Cancer 49Breast Carcinoma In Situ 47Prostatic Neoplasms 42Melanoma 38Pancreatic Neoplasms 37Stomach Neoplasms 32Uterine Cervical Neoplasms 28HER2-positive Breast Cancer 28Sarcoma 27Endometrial Neoplasms 25Head and Neck Neoplasms 24Recurrence 23Colonic Neoplasms 22Carcinoma, Renal Cell 21Carcinoma, Ovarian Epithelial 21Small Cell Lung Carcinoma 20Multiple Myeloma 20Carcinoma, Ductal, Breast 20

Interventions

Radiotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HER2-Negative Locally Advanced Breast Cancer × Breast × Clear all
NCT06908668 2025-04-03

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
170 enrolled
Breast

HER2-Negative Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡